2026 Day 2 AgendaTuesday, 28 April 2026 - ET (Eastern Time, GMT-05:00)

As Life Sciences organizations navigate increasing scrutiny around transparency, reporting, and HCP engagement, AI is moving from experimentation to operational reality.

In this session, PwC demonstrates how AI is being applied across the HCP engagement lifecycle—from fair market value tiering and recipient identification to screening, matching, monitoring, and reporting. Drawing from real-world implementation experience and evolving regulatory expectations, we explore how organizations can enhance compliance, reduce operational friction, and enable more strategic HCP engagement.

Attendees will see how AI-enabled tools are improving:

• Fair Market Value (FMV) tiering and benchmarking
• Recipient screening and risk identification
• Recipient matching and identification accuracy
• Ongoing recipient monitoring
• Transparency reporting efficiency

The future of HCP engagement isn’t just automated—it’s intelligent, risk-informed, and operationally embedded

• Audience icebreaker activities during the Chair’s opening session

• FCPA takeaways for updating risk management, internal investigations and compliance strategies
• Navigating tariffs and sanctions - how are compliance teams adapting to new geoeconomics trends
• What does it now take to manage a global team, keep everyone on the same page and tackle compliance calls?
• Establishing compliance standards across varied geographies: developing a core program with regional flexibility

• Collaborating with HR to integrate compliance into a company’s culture and foster an inclusive and engaged workplace
• Why and when employees feel comfortable speaking up
• Practical strategies to empower employees
• Insights from recent government guidelines on fostering a strong compliance culture
• Proactive steps to identify and address issues before they escalate

• Decoding OIG enforcement: scrutinizing recent OIG settlements and their implications

• Turning guidance into controls: aligning programs with OIG’s guidance and recent advisory opinions

• Commentary on the latest developments from DOJ
• Update on DOJ’s health care fraud, FCPA, and other corporate enforcement
• DOJ guidance to prosecutors and its significance for pharmaceutical companies
• The current state of False Claims Act litigation

• FDA developments and enforcement
• Telemedicine and direct sales
• Specialty pharmacies and product services
• Other trending issues

Compliance is shifting from dashboards to decisions, from detection to prevention. This session spotlights how leading organizations are using AI to transform fragmented audit, monitoring and investigations data into actionable insights that drive faster, smarter risk decisions. Through real-world case studies, we’ll explore what’s working now and what’s next.

You’ll hear how companies are:

• Using AI-driven analytics to flag anomalies, detect emerging risks, and optimize field and digital monitoring.

• Turning disparate data into prioritized risk insights that guide proactive action.

• Building right-sized, cost-effective AI capabilities across pharma and biotech.

• Leveraging automation to reduce investigation time, cut costs, and improve accuracy.

• Harnessing predictive analytics and GenAI to shape the future of compliance operations.

• How can we ensure we are communicating in every way we can communicate whilst remaining compliant?
• Interactions with GPOs – examining the types of interactions with field roles, what they can talk about and what can they do
• Medical commercial interactions: helping Compliance keep pace with agile approaches
• Considerations when using scientific platforms to engage HCPs

Get inspired with three rapid-fire, 10-minute case studies that deliver actionable insights. Learn how industry leaders tackle real-world challenges, uncover upside opportunities, and optimize resources for success.